75 Results for "

neutralizing monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:
Products (75)

75 Results for "neutralizing monoclonal antibody" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-P99340
CAS No.: 2423014-07-5
Synonyms: VIR 7831; GSK-4182136

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9924
CAS No.: 1143503-69-8
Synonyms: LY2439821

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99305
CAS No.: 272780-74-2
Synonyms: CAT-192; Anti-TGFB1 Recombinant antibody

Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99275
CAS No.: 1262787-83-6
Synonyms: AMG-888; U3-1287

Target:  

EGFR Akt ERK PARP Survivin

Research Areas:  

Cancer

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99756
CAS No.: 1989556-22-0
Synonyms: MEDI8897

Target:  

RSV

Research Areas:  

Infection

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99020
CAS No.: 948564-73-6
Synonyms: GC1008

Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology Cancer

Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9953
CAS No.: 428863-50-7
Synonyms: Certolizumab; CDP870

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99053
CAS No.: 1044515-88-9
Synonyms: CAT354
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P990071
CAS No.: 2489584-93-0
Synonyms: LY-3016859
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108810
CAS No.: 914613-48-2
Purity:  99.64%
Synonyms: Ilaris; ACZ 885
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990876
CAS No.: 2911580-96-4
Synonyms: PF-06480605 (WT IgG1); RVT-3101 (WT IgG1)
Target:  

TNF Receptor NF-κB IFNAR

Research Areas:  

Inflammation/Immunology

Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99604
CAS No.: 2420563-99-9
Synonyms: AZD-1061; COV2-2130

Target:  

SARS-CoV

Research Areas:  

Infection

Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99177
CAS No.: 2305638-98-4

Target:  

Inhibitory Antibodies

Research Areas:  

Cardiovascular Disease Infection

Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99342
CAS No.: 2415933-40-1
Synonyms: REGN10987

Target:  

SARS-CoV

Research Areas:  

Infection

Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99792
CAS No.: 2449086-91-1
Synonyms: NM57; rhRIG

Target:  

RABV

Research Areas:  

Infection

Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
loading...
    loading...
Cat. No.: HY-P99486
CAS No.: 339308-60-0
Synonyms: ABT-874

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
loading...
    loading...
Cat. No.: HY-P9945
CAS No.: 196078-29-2
Synonyms: SB 240563
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
loading...
    loading...
Cat. No.: HY-P9945A
CAS No.: 196078-29-2

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
loading...
    loading...
Cat. No.: HY-P99111
CAS No.: 476181-74-5
Synonyms: CNTO-148
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
loading...
    loading...